ContraFect Corp (NASDAQ:CFRX) rose 9.1% during mid-day trading on Friday . The stock traded as high as $0.50 and last traded at $0.48, approximately 129,342 shares traded hands during trading. A decline of 87% from the average daily volume of 1,034,459 shares. The stock had previously closed at $0.44.
CFRX has been the subject of several analyst reports. Maxim Group initiated coverage on shares of ContraFect in a report on Tuesday, June 11th. They set a “buy” rating for the company. Chardan Capital reissued a “buy” rating on shares of FORESIGHT AUTON/S in a report on Wednesday, May 15th. Finally, ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.
The company has a debt-to-equity ratio of 0.20, a current ratio of 4.23 and a quick ratio of 4.23. The business has a 50-day moving average price of $0.48. The company has a market cap of $37.91 million, a P/E ratio of -1.29 and a beta of 0.08.
ContraFect (NASDAQ:CFRX) last issued its earnings results on Friday, May 10th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.26. As a group, sell-side analysts expect that ContraFect Corp will post -0.07 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of CFRX. Hartwell J M Limited Partnership grew its position in ContraFect by 150.0% during the first quarter. Hartwell J M Limited Partnership now owns 100,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 60,000 shares during the period. Northern Trust Corp grew its position in shares of ContraFect by 46.5% in the fourth quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 36,239 shares during the last quarter. White Pine Capital LLC grew its position in shares of ContraFect by 207.9% in the first quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 612,700 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of ContraFect by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock valued at $578,000 after purchasing an additional 29,009 shares during the last quarter. Institutional investors own 37.60% of the company’s stock.
About ContraFect (NASDAQ:CFRX)
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Article: Buy Rating
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.